DUBLIN – Amryt Pharma plc raised $60 million in new equity financing to complete its all-stock takeover of Aegerion Pharmaceuticals Inc., creating a global rare diseases company with three marketed products, a U.S. commercial infrastructure and a couple of near-term opportunities to expand its portfolio.
DUBLIN – Shares in Gensight Biologics SA gained as much as 25% Monday as the company reported 96-week data from the phase III Rescue trial of its GS-010 gene therapy treatment for patients with Leber hereditary optical neuropathy (LHON) arising from the G11778A mutation in the mitochondrial gene encoding NADH dehydrogenase 4 (ND4).
DUBLIN – Versantis AG raised CHF16 million (US$16.1 million) in a series B round to progress clinical trials of a liposomal-based fluid in development for eliminating ammonia and other toxic metabolites from the circulation of patients in acute stages of liver failure who are undergoing peritoneal dialysis.
DUBLIN – Versantis AG raised CHF16 million (US$16.1 million) in a series B round to progress clinical trials of a liposomal-based fluid in development for eliminating ammonia and other toxic metabolites from the circulation of patients in acute stages of liver failure who are undergoing peritoneal dialysis.
DUBLIN – Themis Bioscience GmbH closed a €40 million (US$44.3 million) series D round that will enable it to complete an imminent phase III trial of a candidate vaccine for Chikungunya virus, MV-Chik, and to undertake its first clinical studies of its measles virus vector in oncology indications.
DUBLIN – H. Lundbeck A/S is entering the crowded marketplace for antibody-based migraine therapies by acquiring Alder Biopharmaceuticals Inc. for up to $1.95 billion net of cash.
DUBLIN – Inotrem SA raised €39 million (US$42.9 million) in a series B round to finance a phase IIb trial of its first-in-class septic shock drug candidate, nangibotide, along with a candidate biomarker that may enable it to select patients most likely to benefit from the therapy.
DUBLIN – Genenta Science Srl raised €13.2 million (US$14.6 million) in new funding to progress its genetically engineered autologous hematopoietic progenitor cell therapy designed to reprogram the immunological milieu within the tumor microenvironment.
DUBLIN – Repare Therapeutics Inc. raised $82.5 million in a series B round to progress its pipeline of precision oncology drugs that target vulnerabilities in cancer cells arising from combinations of synthetically lethal mutations.
DUBLIN – Gyroscope Therapeutics Ltd. raised £50.4 million (US$60.5 million) to further development of GT-005, its clinical-stage gene therapy for treating dry age-related macular degeneration (AMD), and to advance a second-generation of the subretinal delivery system it gained through its recent merger with Orbit Biomedical Ltd.
